However, over the past two decades a major scientific shift has occurred. Researchers now recognise that trillions of micro-organisms living in and on the human body, collectively called the microbiome, play an essential role in health.

This insight has given rise to microbiome medicine: a field focused on understanding and treating disease through the manipulation of microbial communities. Scientists increasingly describe the microbiome as a functional “organ” that interacts with digestion, metabolism, immunity, inflammation, and even brain signaling.

The largest and most studied microbiome resides in the gastrointestinal tract. The human gut contains thousands of microbial species that help digest food, produce vitamins, regulate immune responses, and generate signaling molecules called metabolites. Disturbances in this ecosystem- often called dysbiosis, have been linked to conditions ranging from inflammatory bowel disease to obesity, diabetes, allergies, liver disease, and certain neurological disorders.

Importantly, microbiome medicine is no longer purely theoretical. It is now producing clinically approved therapies, attracting major pharmaceutical investment, and reshaping how researchers think about chronic disease.

What Is Microbiome Medicine?

Microbiome medicine refers to therapeutic strategies that intentionally modify microbial communities or use microbial products to improve health. These approaches can include:

• Probiotics and targeted bacterial strains
• Prebiotics that nourish beneficial microbes
• Dietary interventions
• Fecal microbiota transplantation (FMT)
• Live biotherapeutic products (LBPs)
• Engineered bacteria designed to deliver therapeutic compounds

Why the Field Matters

Microbiome medicine is changing how researchers understand disease itself. Rather than viewing illnesses as isolated failures of a single organ or gene, scientists increasingly see many chronic conditions as disruptions in complex human-microbial ecosystems. The gut microbiome alone contains trillions of microorganisms carrying millions of genes, influencing metabolism, immune signaling, drug metabolism, inflammation, and communication between the gut and brain.

Researchers now know that microbial metabolites can affect how immune cells mature, how medications are processed, and how intestinal barriers function. This systems-level influence is why the microbiome is now being studied across gastroenterology, oncology, neurology, endocrinology, dermatology, and psychiatry. Importantly, microbiome patterns are also shaped by geography, diet, antibiotic exposure, and environmental conditions, making the field globally relevant rather than centered on one population model.

Three areas are receiving particular attention:

1. Immune Regulation

The gut microbiome helps regulate the immune system. Certain bacterial metabolites, particularly short-chain fatty acids such as butyrate, help maintain intestinal barrier integrity and reduce inflammation. Dysbiosis has been associated with inflammatory bowel disease, asthma, rheumatoid arthritis, and eczema.

2. Metabolism and Chronic Disease

Gut microbes influence glucose metabolism, appetite signaling, lipid regulation, and energy extraction from food. Scientists are exploring whether microbiome-targeted therapies could eventually support treatment for obesity, metabolic syndrome, and type 2 diabetes.

3. The Gut-Brain Axis

One of the most intriguing research areas is the “gut-brain axis,” the biochemical communication network linking intestinal microbes with the nervous system. Researchers are investigating microbiome involvement in depression, anxiety, autism spectrum disorder, Parkinson’s disease, and Alzheimer’s disease, although many findings remain preliminary.

Major Developments from the Past Two Years

FDA-Approved Live Biotherapeutic Products

One of the most important recent developments has been the clinical rollout of FDA-approved live biotherapeutic products for recurrent Clostridioides difficile infection.

Products such as Rebyota and Vowst are designed to restore healthy gut microbial diversity after repeated antibiotic exposure. Their approval established one of the first regulatory pathways for microbiome-derived therapeutics and demonstrated that microbial ecosystem restoration can produce measurable clinical outcomes.

This regulatory shift has influenced research programs in the United Kingdom and European Union as health systems increasingly investigate microbiome therapies as part of broader antimicrobial resistance and precision medicine strategies.

Israel’s Expanding Microbiome Sector

Israel has become an increasingly active center for microbiome biotechnology and translational medicine. In 2024, Israeli company Biomica reported encouraging early-stage clinical data for BMC128, a microbiome-based immuno-oncology therapy being tested alongside checkpoint inhibitors for resistant cancers including melanoma and lung cancer.

Israel has also seen growing investment in microbiome-linked women’s health research, including clinical work on endometriosis therapies.

India and Asia-Pacific Research Expansion

India has emerged as an increasingly important contributor to microbiome science because of its population diversity, dietary variation, and antibiotic exposure patterns. Researchers have emphasised that microbiome medicine cannot rely entirely on Western datasets, since microbial ecosystems vary substantially across populations.

Meanwhile, Singapore has integrated microbiome medicine into broader precision medicine initiatives through research programs focused on cancer, metabolic disease, aging, and environmental health.

Across Hong Kong, Indonesia, and the wider Asia-Pacific region, microbiome research capacity is also expanding through university and public health collaborations studying urbanization, diet transitions, diabetes, and antimicrobial resistance.

What to Watch Over the Next Few Years

Precision Microbiome Therapeutics

Researchers in the United States, United Kingdom, Singapore, Israel, and the European Union are now starting to combine microbiome sequencing with artificial intelligence and metabolomics to identify which microbial pathways directly influence disease. Rather than focusing simply on “good” or “bad” bacteria, scientists are beginning to identify the metabolites and immune interactions that matter most clinically.

This could eventually lead to individualised microbial therapies tailored to a patient’s immune profile, genetics, diet, and medication response.

Engineered Bacteria and Synthetic Microbiomes

One of the most closely watched areas involves engineered microbes.

Scientists are now developing programmable bacteria capable of sensing inflammation, producing therapeutic compounds, or competing against drug-resistant organisms. Experimental synthetic microbiome systems are also being explored as tools to reduce multidrug-resistant pathogens and improve infectious disease management.

Several research groups in Europe, Singapore, Israel, and the United States are expected to advance engineered live biotherapeutics into larger human trials within the next two years.

Microbiome-Guided Cancer Therapy

Cancer immunotherapy remains one of the field’s most promising applications.

Researchers are increasingly studying whether microbial signatures can predict who responds well to checkpoint inhibitors and other advanced cancer therapies. Israeli and European biotechnology companies are among those leading clinical development in this area.

If ongoing studies remain positive, microbiome-guided oncology could become one of the first major expansions of microbiome medicine beyond gastrointestinal disease.

My Final Thoughts

Microbiome medicine represents one of the most significant conceptual shifts in modern biomedical science. Rather than viewing microbes solely as threats, researchers now recognise them as deeply integrated participants in human physiology.

The field is still developing, and many proposed applications remain experimental. Over the next several years, the combination of genomics, synthetic biology, artificial intelligence, and systems medicine is likely to push microbiome therapeutics into increasingly sophisticated territory. Whether through engineered bacteria, personalised microbial interventions, or microbiome-guided diagnostics, medicine may soon rely not only on treating the human body itself, but also on treating the microbial world that lives within it.